Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
odanacatib
Description:
Odanacatib is an investigational cathepsin K inhibitor studied as a drug for osteoporosis and bone loss.
Primary topic:
Bone health and osteoporosis research (57%)
Related topics:
Bone health and osteoporosis research (57%),
Bone Metabolism and Diseases (9%),
Protease and Inhibitor Mechanisms (7%)
Wikidata ID:
wiki/Q2014070
OpenAlex ID:
keywords/odanacatib
Osteoporosis: now and the future
2011
·
Tilman D Rachner
, Sundeep Khosla
, et al.
·
The Lancet
·
3,007
Osteoporosis treatment: recent developments and ongoing challenges
2017
·
Sundeep Khosla
, Lorenz C Hofbauer
·
The Lancet Diabetes & Endocrinology
·
1,122
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
2016
·
Bente Langdahl
, Serge Ferrari
, et al.
·
Therapeutic Advances in Musculoskeletal Disease
·
535
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
2008
·
Jacques Yves Gauthier
, Nathalie Chauret
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
526
Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer
2019
·
Rui Li
, Rui Zhou
, et al.
·
Cell Death and Differentiation
·
421
PDF
Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density
2009
·
Henry G Bone
, Michael R McClung
, et al.
·
Journal of Bone and Mineral Research
·
352
A Crisis in the Treatment of Osteoporosis
2016
·
Sundeep Khosla
, Elizabeth Shane
·
Journal of Bone and Mineral Research
·
350
Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis
2011
·
Aline G. Costa
, Natalie E. Cusano
, et al.
·
Nature Reviews Rheumatology
·
329
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned
2017
·
Matthew T Drake
, Bart L Clarke
, et al.
·
Endocrine Reviews
·
307
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
2020
·
Dennis M Black
, Douglas C Bauer
, et al.
·
The Lancet Diabetes & Endocrinology
·
256
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect
2010
·
John A Eisman
, Henry G Bone
, et al.
·
Journal of Bone and Mineral Research
·
254
PDF
Cathepsin K: The Action in and Beyond Bone
2020
·
Rongchen Dai
, Zeting Wu
, et al.
·
Frontiers in Cell and Developmental Biology
·
246
PDF
Development of a Direct Photocatalytic C–H Fluorination for the Preparative Synthesis of Odanacatib
2015
·
Shira D. Halperin
, Daniel Kwon
, et al.
·
Organic Letters
·
189
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
2019
·
Michael R McClung
, Michelle L O'Donoghue
, et al.
·
The Lancet Diabetes & Endocrinology
·
183
Potential new drug targets for osteoporosis
2008
·
Chad Deal
·
Nature Clinical Practice Rheumatology
·
177
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study
2012
·
Bente Langdahl
, Neil Binkley
, et al.
·
Journal of Bone and Mineral Research
·
166
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies
2009
·
S A Stoch
, S Zajic
, et al.
·
Clinical Pharmacology & Therapeutics
·
166
Merck & Co. drops osteoporosis drug odanacatib
2016
·
Asher Mullard
·
Nature Reviews Drug Discovery
·
160
New targets for intervention in the treatment of postmenopausal osteoporosis
2011
·
E. Michael Lewiecki
·
Nature Reviews Rheumatology
·
159
The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial
2010
·
Anders Bonde Jensen
, Christopher Wynne
, et al.
·
Clinical Breast Cancer
·
158
New understanding and treatments for osteoporosis
2011
·
G. Mazziotti
, J. Bilezikian
, et al.
·
Endocrine
·
156
Cathepsin K: a unique collagenolytic cysteine peptidase
2013
·
Marko Novinec
, Brigita Lenarčič
·
Biological Chemistry
·
154
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
2014
·
H. G. Bone
, D. W. Dempster
, et al.
·
Osteoporosis International
·
147
PDF
Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey
2011
·
Tara Cusick
, Charles M Chen
, et al.
·
Journal of Bone and Mineral Research
·
139
Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins
2010
·
Maxim Frizler
, Marit Stirnberg
, et al.
·
Current Topics in Medicinal Chemistry
·
132
Show more works
View as search
Works count:
404
Citation count:
15,530
Year
Topic
Type